Skip to main content
Premium Trial:

Request an Annual Quote

Prometheus Laboratories PredictrPK IFX

Prometheus Laboratories has launched the PredictrPK IFX test to help guide the dosing of biologics for inflammatory bowel disease. The test leverages homogenous mobility shift assay technology, originally incorporated in Prometheus Labs' Anser test, along with other markers and variables in a machine-learning algorithm. According to the firm, current therapeutic drug monitoring methods provide only historical point-in-time drug and antibody level measurements, while PredictrPK IFX "provides a forward-looking view to expeditiously guide achievement of target drug levels."